181 related articles for article (PubMed ID: 38233702)
1. Comparison of standardized prophylactic high-dose and intrathecal methotrexate for DLBCL with a high risk of CNS relapse.
Akimoto M; Miyazaki T; Takahashi H; Saigusa Y; Takeda T; Hibino Y; Tokunaga M; Ohashi T; Matsumura A; Teshigawara H; Suzuki T; Teranaka H; Nakajima Y; Matsumoto K; Hashimoto C; Fujimaki K; Fujita H; Sakai R; Fujisawa S; Nakajima H
Int J Hematol; 2024 Feb; 119(2):164-172. PubMed ID: 38233702
[TBL] [Abstract][Full Text] [Related]
2. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.
Wilson MR; Eyre TA; Kirkwood AA; Wong Doo N; Soussain C; Choquet S; Martinez-Calle N; Preston G; Ahearne M; Schorb E; Moles-Moreau MP; Ku M; Rusconi C; Khwaja J; Narkhede M; Lewis KL; Calimeri T; Durot E; Renaud L; Øvlisen AK; McIlroy G; Ebsworth TJ; Elliot J; Santarsieri A; Ricard L; Shah N; Liu Q; Zayac AS; Vassallo F; Lebras L; Roulin L; Lombion N; Manos K; Fernandez R; Hamad N; Lopez-Garcia A; O'Mahony D; Gounder P; Forgeard N; Lees C; Agbetiafa K; Strüßmann T; Htut TW; Clavert A; Scott H; Guidetti A; Barlow BR; Tchernonog E; Smith J; Miall F; Fox CP; Cheah CY; El Galaly TC; Ferreri AJM; Cwynarski K; McKay P
Blood; 2022 Apr; 139(16):2499-2511. PubMed ID: 34995350
[TBL] [Abstract][Full Text] [Related]
3. Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma.
Puckrin R; El Darsa H; Ghosh S; Peters A; Owen C; Stewart D
Am J Hematol; 2021 Jul; 96(7):764-771. PubMed ID: 33811794
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent-based analysis.
Jeong H; Cho H; Kim H; Chae H; Lee JB; Lee K; Kim S; Lee SW; Ryu JS; Kim KW; Chae EJ; Huh J; Park CS; Yoon DH; Suh C
Blood Adv; 2021 Apr; 5(8):2142-2152. PubMed ID: 33881464
[TBL] [Abstract][Full Text] [Related]
5. Optimization of high-dose methotrexate prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma: a multicenter analysis.
Fang Y; Su N; Ma S; Cai J; Zhong L; Li W; Huang H; Li Z; Huang H; Xia Y; Liu P; Guo L; Li Z; Wu Y; Tian X; Wang J; Zhang Y; Cai Q
Ann Hematol; 2022 Mar; 101(3):595-605. PubMed ID: 34985557
[TBL] [Abstract][Full Text] [Related]
6. The role of central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: A network meta-analysis.
Lin Z; Chen X; Liu L; Zeng H; Li Z; Xu B
Crit Rev Oncol Hematol; 2022 Aug; 176():103756. PubMed ID: 35809794
[TBL] [Abstract][Full Text] [Related]
7. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery.
Wilson MR; Eyre TA; Martinez-Calle N; Ahearne M; Parsons KE; Preston G; Khwaja J; Schofield J; Elliot J; Mula Kh A; Shah N; Cheung CK; Timmins MA; Creasey T; Linton K; Smith J; Fox CP; Miall F; Cwynarski K; McKay P
Blood Adv; 2020 Aug; 4(15):3586-3593. PubMed ID: 32761231
[TBL] [Abstract][Full Text] [Related]
8. Prophylaxis strategies containing high dose intravenous methotrexate on preventing CNS relapse for patients with diffuse large B-cell lymphoma at intermediate to high risk: A study based on 12 cohorts in the rituximab era.
Zhang N; Xu D; Liu B; Shi X; Xie X; Wang Z
Int Immunopharmacol; 2022 Dec; 113(Pt A):109299. PubMed ID: 36252471
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse.
Bobillo S; Joffe E; Sermer D; Mondello P; Ghione P; Caron PC; Hamilton A; Hamlin PA; Horwitz SM; Kumar A; Matasar MJ; Batlevi CL; Moskowitz A; Noy A; Owens CN; Palomba ML; Straus D; von Keudell G; Dogan A; Zelenetz AD; Seshan VE; Younes A
Blood Cancer J; 2021 Jun; 11(6):113. PubMed ID: 34135307
[TBL] [Abstract][Full Text] [Related]
10. Factors Influencing Physician Discretion to Administer CNS Prophylaxis in Diffuse Large B Cell Lymphoma: A Single Institution Retrospective Study.
Hino C; Lacy C; Brothers J; Cao H; Mirshahidi H; Park K; Akhtari M
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):764-771. PubMed ID: 37482525
[TBL] [Abstract][Full Text] [Related]
11. Model for Predicting Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma and Discussion of Prophylaxis Measures.
Cui JY; Liu YF; Gao B; Mi L; Deng LJ; Zhu J; Hou SL
World Neurosurg; 2023 Nov; 179():e387-e396. PubMed ID: 37652134
[TBL] [Abstract][Full Text] [Related]
12. [Risk assessment and prophylactic treatment strategies for central nervous system relapse of diffuse large B-cell lymphoma].
Miyazaki K
Rinsho Ketsueki; 2023; 64(6):490-496. PubMed ID: 37407473
[TBL] [Abstract][Full Text] [Related]
13. Diffuse large B-cell lymphoma at risk of secondary CNS involvement: The inefficacy of intravenous high-dose methotrexate CNS prophylaxis and the importance of baseline cerebrospinal fluid analysis.
Bennett R; Ruskova A; Coomarasamy C; Theakston E; Berkahn L; Jackson S; Christophers M; Wong S; Issa S
Am J Hematol; 2023 Jul; 98(7):1070-1079. PubMed ID: 37161765
[TBL] [Abstract][Full Text] [Related]
14. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
15. Real-World Data (RWD) on the 3-Year Follow-Up Outcomes of Different CNS Prophylaxis Strategies Across CNS-IPI Risk Groups in Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma.
Faqah A; Asif S; Goksu SY; Sheikh HS
JCO Glob Oncol; 2021 Apr; 7():486-494. PubMed ID: 33835825
[TBL] [Abstract][Full Text] [Related]
16. Limited efficacy of high-dose methotrexate to prevent the central nervous system relapse in patients with IVLBCL.
Terao T; Tsushima T; Ikeda D; Fukumoto A; Kamura Y; Kuzume A; Tabata R; Miura D; Narita K; Takeuchi M; Matsue K
Leuk Lymphoma; 2022 Dec; 63(14):3394-3401. PubMed ID: 36111741
[TBL] [Abstract][Full Text] [Related]
17. Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.
Kansara R
Curr Treat Options Oncol; 2018 Sep; 19(11):52. PubMed ID: 30203318
[TBL] [Abstract][Full Text] [Related]
18. Primary breast diffuse large B-cell lymphoma in the rituximab era: A retrospective study of the Chinese Southwest Oncology Group.
Weng H; Shrestha PR; Hong H; Chen Z; Yu L; Yao Y; Zhang Z; Zou L; Zhu B; Zhou H; Liu X; Liu Y; Guo H; Huang H; Lin T
Cancer Med; 2023 Dec; 12(23):21188-21198. PubMed ID: 37997571
[TBL] [Abstract][Full Text] [Related]
19. Systemic HD-MTX for CNS prophylaxis in high-risk DLBCL patients: a prospectively collected, single-center cohort analysis.
Lee K; Yoon DH; Hong JY; Kim S; Lee K; Kang EH; Huh J; Park CS; Lee SW; Suh C
Int J Hematol; 2019 Jul; 110(1):86-94. PubMed ID: 31115880
[TBL] [Abstract][Full Text] [Related]
20. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma.
Arkenau HT; Chong G; Cunningham D; Watkins D; Agarwal R; Sirohi B; Trumper M; Norman A; Wotherspoon A; Horwich A
Ann Oncol; 2007 Mar; 18(3):541-5. PubMed ID: 17164228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
